Abstract:The PWWP domain was first identified as a structural motif of 100-130 amino acids in the WHSC1 protein and predicted to be a protein-protein interaction domain. It belongs to the Tudor domain 'Royal Family', which consists of Tudor, chromodomain, MBT and PWWP domains. While Tudor, chromodomain and MBT domains have long been known to bind methylated histones, PWWP was shown to exhibit histone binding ability only until recently.The PWWP domain has been shown to be a DNA binding domain, but sequence analysis and previous structural studies show that the PWWP domain exhibits significant similarity to other 'Royal Family' members, implying that the PWWP domain has the potential to bind histones. In order to further explore the function of the PWWP domain, we used the protein family approach to determine the crystal structures of the PWWP domains from seven different human proteins. Our fluorescence polarization binding studies show that PWWP domains have weak histone binding ability, which is also confirmed by our NMR titration experiments. Furthermore, we determined the crystal structures of the BRPF1 PWWP domain in complex with H3K36me3, and HDGF2 PWWP domain in complex with H3K79me3 and H4K20me3.PWWP proteins constitute a new family of methyl lysine histone binders. The PWWP domain consists of three motifs: a canonical β-barrel core, an insertion motif between the second and third β-strands and a C-terminal α-helix bundle. Both the canonical β-barrel core and the insertion motif are directly involved in histone binding. The PWWP domain has been previously shown to be a DNA binding domain. Therefore, the PWWP domain exhibits dual functions: binding both DNA and methyllysine histones.This article can also be viewed as an enhanced version in which the text of the article is integrated with interactive 3D representations and animated transitions. Please note that a web plugin is required to access this enhanced functionality. Instructions for the installation and use of the web plugin are available in Text S1.

Inhibitors targeting the PWWP domain-containing proteins

Advances in inhibitor development targeting the PWWP domain

Targeting Bromodomain-Containing Proteins: Research Advances of Drug Discovery

Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors

Targeting Histone Readers: Non-bromodomain Readers

E3 ubiquitin ligase WWP2 as a promising therapeutic target for diverse human diseases

Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer

Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective

Recent Advance on PTP1B Inhibitors and Their Biomedical Applications.

Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders

Chemical inhibitors targeting histone methylation readers

Recent Advances on Small-Molecule Bromodomain-Containing Histone Acetyltransferase Inhibitors.

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

[Targeting the Substrate Binding Domain of Polo-Like Kinase 1: Advances in the Study of PBD1 Inhibitors].

Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8

Current development of CBP/p300 inhibitors in the last decade

Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development

Targeting CBP and p300: Emerging Anticancer Agents

Structural and Histone Binding Ability Characterizations of Human PWWP Domains.

Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment

Epigenetic protein families: a new frontier for drug discovery